

Arizona Conference
on
Developing Therapeutics for Cancer and Immunology

Monday, December 9, 2019

9:00 am – 4:35 pm

Phoenix Biomedical Campus
Biomedical Sciences Partnership Building
475 N. 5th Street. Phoenix AZ

AGENDA

[Register to attend here](#)

8:30 am – 9:00 am	Check-in
9:00 am – 9:10 am	Welcome and Introduction Joann Sweasy (UA), Grant McFadden (ASU), Karen Anderson (ASU)
9:10 am – 10:10 am	Cancer Prevention <u>Co-Chairs: Sherry Chow (UA) and Cynthia Thomson (UA)</u> Sherry Chow (UA): <i>Clinical development of cancer preventive agents: Lessons learned and future opportunities</i> Cynthia Thomson (UA): <i>Evaluation of bioactive food components for cancer prevention</i> Clara Curiel (UA): <i>Innovative skin cancer prevention: From risk factor biomarker discovery to novel targets for therapeutic prevention</i>
10:10 am – 11:10 am	Cancer and Microbiome <u>Co-Chairs: Melissa Herbst-Kralovetz (UA) and Greg Caporaso (NAU)</u> Sarah Highlander (TGen): <i>Immuno-oncology and the gut microbiome</i> Greg Caporaso (NAU): <i>Developing and applying the next generation of microbiome bioinformatics tools to advance cancer research</i> Melissa Herbst-Kralovetz (UA): <i>Predicting features of the cervical cancer microenvironment through integrated multi-omics analyses</i>
11:10 am – 11:20 am	Break
11:20 am – 12:00 pm	Keynote 1 Dom Spinella (Translational Medicine Partners, Inc.) <i>Cancer immunotherapy: Past, present, future</i>
12:00 pm – 1:20 pm	Lunch
1:20 pm – 2:20 pm	Antigen Discovery and Translation to Cellular Therapies <u>Chair: Karen Anderson (ASU)</u> Karen Anderson (ASU): <i>Neo-antigen identification for cancer immunotherapy</i> Michael Gustafson (Mayo): <i>Identifying immunological barriers to cancer immunotherapy</i>

2:20 pm – 3:40 pm

Cancer Immunology

Co-Chairs: Grant McFadden (ASU) and Karen Hastings (UA)

Karen Hastings (UA): *High GILT expression and an active and intact MHC class II antigen presentation pathway are associated with improved survival in melanoma*

Joe Blattman (ASU): *Enhancing immunotherapy by modulating T cell homing*

Dominik Schenten (UA): *Control of adaptive immunity by the innate signaling adaptor MAVS*

Marion Curtis (Mayo): *Tumor antigen-directed immunotherapy for ovarian cancer*

3:40 pm – 3:50 pm

Break

3:50 pm – 4:30 pm

Keynote 2

David Kranz (University of Illinois at Urbana-Champaign):
Engineering receptors for T cell therapies of cancer

4:30 pm – 4:35 pm

Wrap up

4:35 pm onwards

Networking

Canyon Café in Arizona Center

Cash bar happy hour



THE UNIVERSITY OF ARIZONA
Cancer Center



ARIZONA DEPARTMENT
OF HEALTH SERVICES
ARIZONA BIOMEDICAL RESEARCH CENTRE